Jacobsen Biotech ApS: Financial statements 2024
CVR: 43211218
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Jacobsen Biotech ApS (CVR 43211218) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 0 and a net result of DKK -2,872 compared with DKK -17,556 the year before. Equity in the 2024 report amounted to DKK 21,993. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -2,872
- Equity
- DKK 21,993
- Total Assets
- DKK 21,993
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | 0 | -3 t. | 22 t. | - |
| 2023 | 4 t. | -15 t. | -18 t. | 25 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Jacobsen Biotech ApS has published its annual report for 2023. Revenue came to DKK 4,000, and the net result was DKK -17,556.
About Jacobsen Biotech ApS
Jacobsen Biotech ApS is a Danish company of the type Anpartsselskab based in Harlev J, founded in 2022. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Kristian Mark Jacobsen. The company is owned by Kristian Mark Jacobsen. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -7,890 and a net result of DKK -7,890 compared with DKK -2,872 the year before. Equity in the 2025 report amounted to DKK 14,103.